Intellectual Property Firm for Pharmaceuticals
The global pharmaceutical market is enormous as global spending on prescription drugs has mushroomed. However, drug companies are facing a number of intellectual property-related challenges that will no doubt negatively affect their bottom line. The biggest challenge is that many drugs are going “off-patent” as their patents expire. This opens the door for other companies to manufacture the drug as a generic, which can be manufactured and distributed without patent protection. The competitive implications of this are daunting.
In addition, a host of new patent challenges are posed by the rapidly-growing emerging markets in China, India and Brazil. In these countries, international patent enforcement is varied. For example, when there is a great perceived need for a drug, the patent is violated and the drug is manufactured and distributed locally.
Graeser Associates International (GAI), an international intellectual property company that provides a wide range of IP services to clients in these markets, helps clients with these challenges. GAI specializes in diverse pharmaceutical disciplines, including innovative chemical entities, synthetic chemistry, drug delivery systems, pharmaceutical formulations, methods of treatment, drug synthesis protocols, industrial chemistry, and drug discovery systems. GAI addresses the numerous aspects of IP protection throughout the pharmaceutical life cycle. The company’s expertise is derived from the GAI team’s experience with international pharmaceutical industry clients and the pursuit of academic credentials in pharmaceutical-related technologies and development.
GAI assists clients in devising IP strategies that conform to a variety of patent laws and regulations and that are sufficiently flexible to be successful. In particular, GAI:
- helps mitigate risks associated with the rapid increase in competition
- provides thorough analyses, sophisticated solutions and Freedom to Operate opinions
- provides litigation support services, with analysis of potential or actual issues in litigation
GAI's professional staff also has country-specific experience in different business models within the pharmaceutical industry. For example, companies which rely on completely proprietary active ingredients and formulations for their business model have very different IP needs from companies which rely upon generic active ingredients.
GAI keeps current on the R&D and recent developments in the global pharmaceutical industry, both on the scientific and legal fronts, enhancing their ability to provide strategies for clients that address the IP issues affecting their extensions into new countries and markets.